Why Choose Us for Relapsed or Refractory Cancer Treatment

The Center for Precision Medicine for High-Risk Pediatric Cancer at Children's Hospital of Philadelphia (CHOP) is co-led by a team of world-class experts.

Theodore Laetsch, MD, leads both the Developmental Therapeutics Program and the Very Rare Malignant Tumors Program at CHOP, as well as holds national leadership roles in each of these areas within the Children’s Oncology Group (COG). He has extensive experience in molecularly targeted therapies/precision medicine and early-phase clinical trials.

Marilyn Li, MD, MS, is the Vice Chief of the Division of Genomic Diagnostics and Director of Cancer Genomic Diagnostics at CHOP. She developed and implemented the current clinical cancer genomic testing platform at CHOP, which is widely used both within CHOP and by referring providers and has sequenced over 4,000 cancers.

Kai Tan, PhD, is the Co-leader of the Pediatric Oncology Program at Penn Medicine’s Abramson Cancer Center and the Director of CHOP’s Center for Single Cell Biology. He has extensive expertise in cancer genomics and leads the center’s preclinical single cell profiling studies. These studies are designed to evaluate tumors at the cellular level to identify genetic changes within individual tumors.

Adam Resnick, PhD, is the Director of the Center for Data-Driven Discovery in Biomedicine and the Scientific Director of the Children’s Brain Tumor Network, an associated CHOP-based repository. He leads the effort to integrate the genetic, clinical, and outcome data in order to better understand pediatric cancers and develop visualization and tools to support physician decision-making.